DIOSynVax

Cipla Limited ’s efforts to shepherd Moderna, Inc. ’s messenger RNA (mRNA) COVID-19 vaccine to India may not have gone as per plan in 2021, but the Indian company isn’t going to sit on the sidelines

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Mersana Ends 2022 With Third Big Pharma